Back to Search Start Over

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Authors :
Jan-Henning Klusmann
M Labuhn
Oriol Alejo-Valle
Dirk Reinhardt
Andrea Sinz
Stephan Emmrich
Michelle Ng
Marius Flasinski
Raj Bhayadia
E Regenyi
Dirk Heckl
Karoline Weigert
Hasan Issa
Christoph Beyer
Christian Ihling
Konstantin Schuschel
Marie-Laure Yaspo
Publication Year :
2021
Publisher :
Cold Spring Harbor Laboratory, 2021.

Abstract

Given the plasticity of hematopoietic stem/progenitor cells, multiple routes of differentiation must be blocked during acute myeloid leukemia pathogenesis – the molecular basis of which is incompletely understood. Here we report that post-transcriptional repression of transcription factor ARID3A by miR-125b is a key event in megakaryoblastic leukemia (AMKL) pathogenesis. AMKL is frequently associated with trisomy 21 and GATA1 mutations (GATA1s), and children with Down syndrome are at a high risk of developing this disease. We show that chromosome 21-encoded miR-125b synergizes with Gata1s to drive leukemogenesis in this context. Leveraging forward and reverse genetics, we uncover Arid3a as the main miR-125b target underlying this synergy. We demonstrate that during normal hematopoiesis this transcription factor promotes megakaryocytic differentiation in concert with GATA1 and mediates TGFβ-induced apoptosis and cell cycle arrest in complex with SMAD2/3. While Gata1s mutations perturb erythroid differentiation and induce hyperproliferation of megakaryocytic progenitors, intact ARID3A expression assures their megakaryocytic differentiation and growth restriction. Upon knockdown, these tumor suppressive functions are revoked, causing a dual megakaryocytic/erythroid differentiation blockade and subsequently AMKL. Inversely, restoring ARID3A expression relieves the megakaryocytic differentiation arrest in AMKL patient-derived xenografts. This work illustrates how mutations in lineage-determining transcription factors and perturbation of post-transcriptional gene regulation interplay to block multiple routes of hematopoietic differentiation and cause leukemia. Surmounting this differentiation blockade in megakaryoblastic leukemia by restoring the tumor suppressor ARID3A represents a promising strategy for treating this lethal pediatric disease.Key pointsRepression of megakaryocytic transcription factor ARID3A by miR-125b synergizes with GATA1s to induce leukemiaRestoring ARID3A expression relieves megakaryocytic differentiation arrest in megakaryoblastic leukemiaGraphical abstract

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........363f71aee0ae20cb4a5e3cd9f2d7dccd